Following the suspension of vaccines with active ingredients from Johnson & Johnson in the United States, the U.S. Health Authority has spoken in support of gathering additional information before the CDC’s advisory panel recommends further action. The committee members decided it on Wednesday after several hours of discussions at a short-term emergency meeting. It said there should be another meeting in about a week.
The CDC and FDA on Tuesday recommended suspending vaccines with active ingredients from Johnson & Johnson after six cases of sinus nerve thrombosis were reported in the United States. The expression was recommended “with extreme caution”. American pharmaceutical company Johnson & Johnson has delayed the release of its vaccine in Europe and has suspended all ongoing studies on vaccines with the active ingredient.
So far, according to updated data, more than 7.2 million vaccines were approved in the United States at the end of February and taken in a single dose. According to officials, six women between the ages of 18 and 48 had sinus vein thrombosis within 6 to 13 days of being vaccinated. In all three cases, thrombocytopenia, or a deficiency of platelets, was reported. A woman died.
In the EU, more and more countries are no longer getting vaccinated against Johnson & Johnson. In addition to Austria, the Netherlands, Sweden, Denmark and Italy are currently suspending the vaccine. The European Pharmaceuticals Association (EMA) plans to present an opinion next week.